New $7.6 million NIA grant awarded to IU for Longitudinal Early-onset AD Study

NewsGuard 100/100 Score

Indiana University School of Medicine has been awarded a one-year, $7.6 million grant from the National Institute on Aging (NIA) to establish a network of sites to study early-onset Alzheimer's disease.

The new NIA grant will help establish an infrastructure and begin recruitment for what will be an approximately $45 million research program led by Liana G. Apostolova, MD, Barbara and Peer Baekgaard Professor of Alzheimer's Disease Research at IU School of Medicine. Dr. Apostolova will lead a multi-site longitudinal observational study to better understand how people develop this rare variant of Alzheimer's disease.

While the risk of Alzheimer's disease increases with advancing age, approximately 5 percent of Alzheimer's patients develop symptoms before age 65, with less than 10 percent of these patients carrying known mutations for the disease, Dr. Apostolova said. But despite being highly motivated and having fewer age-related comorbidities compared to late-onset Alzheimer's patients, early-onset patients are commonly excluded from clinical research and therapeutic trials because of their young age or lack of memory loss. Studies suggest high heritability of genetic risk factors in this population, she said.

To help fill this gap, Dr. Apostolova's study, called Longitudinal Early-onset AD Study (LEADS), will establish a network of sites across the United States and will enroll a large cohort of early-onset Alzheimer's disease participants who will provide robust longitudinal clinical and biomarker data. This work will bridge the gap toward future clinical trials and establish an early-onset Alzheimer's disease clinical trial network in the U.S.

"The data collected as part of this study will provide a definitive comparison of the clinical, psychometric, imaging, fluid biomarker and genetic similarities and differences between early-onset and late-onset Alzheimer's disease," Dr. Apostolova said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Alzheimer's may worsen COVID-19 outcomes via olfactory mucosa changes